Delyth Clemett

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

Richard D. Carvajal, Sophie Piperno‐Neumann, Ellen Kapiteijn et al. · Journal of Clinical Oncology · 2018 · 275 citations · Full text

Medicine, Oncology, Pharmacology +15

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.

Solange Peters, Byoung Chul Cho, Niels Reinmuth et al. · Cancer Research · 2019 · 76 citations

Medicine, Oncology, Pharmacology +17

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

Patricia LoRusso, Jeffrey R. Infante, Kevin B. Kim et al. · BMC Cancer · 2017 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

Jeffrey R. Infante, Roger B. Cohen, Kevin B. Kim et al. · Investigational New Drugs · 2017 · 17 citations · Full text

Medicine, Oncology, Pharmacology +16

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.

Solange Peters, Byoung Chul Cho, Niels Reinmuth et al. · Clinical Trials · 2019 · 12 citations

Medicine, Oncology, Pharmacology +17